Center for Molecular and Vascular Research, University of Leuven, Leuven, Belgium.
Hypertension. 2012 Nov;60(5):1088-93. doi: 10.1161/HYPERTENSIONAHA.111.187104. Epub 2012 Sep 17.
Even in the new millennium, arterial hypertension remains a serious condition, with considerable morbidity and mortality worldwide. Crucial in managing the disease is not only lowering arterial blood pressure but also preventing or treating the typical end-organ damage caused by long-lasting and inadequately treated hypertension. In the past decade, it has been shown that microRNAs (miRs) are involved in several hypertension-related pathologies, such as cardiac hypertrophy and fibrosis, hypertensive heart failure, renal fibrosis, kidney failure, and, to a lesser extent, eye disease and hemorrhagic stroke. Whereas others extensively reviewed the role of miRs in atherosclerosis and vascular disease, this review focuses on their role in target organ damage during arterial hypertension. We emphasize the involvement of miRs in pathological end-organ remodeling processes and try to demonstrate some common miR signatures in distinct end organs. Hence, we aimed to provide proof of arterial hypertension being a systemic disease, similar to diabetes mellitus or metabolic syndrome. Furthermore, miRs that act on one particular process in different end organs are interesting therapeutic targets. Some future perspectives in miR research are highlighted with respect to novel therapeutic strategies in the cardiovascular field.
即使在新千年，动脉高血压仍然是一种严重的疾病，在全球范围内有相当高的发病率和死亡率。管理这种疾病的关键不仅在于降低动脉血压，还在于预防或治疗由长期和治疗不当的高血压引起的典型靶器官损伤。在过去的十年中，已经表明 microRNAs（miRs）参与了几种与高血压相关的病理学，如心肌肥厚和纤维化、高血压性心力衰竭、肾纤维化、肾衰竭，以及在较小程度上，眼病和出血性中风。虽然其他人广泛综述了 miRs 在动脉粥样硬化和血管疾病中的作用，但本综述重点介绍了它们在动脉高血压期间对靶器官损伤的作用。我们强调了 miRs 在病理性靶器官重塑过程中的参与，并试图证明在不同靶器官中存在一些共同的 miR 特征。因此，我们旨在提供动脉高血压是一种全身性疾病的证据，类似于糖尿病或代谢综合征。此外，在不同靶器官中对一个特定过程起作用的 miRs 是有趣的治疗靶点。针对心血管领域的新治疗策略，突出了 miR 研究的一些未来展望。
